S&P 500   3,255.58 (-1.92%)
DOW   27,059.34 (-2.16%)
QQQ   262.46 (-1.65%)
AAPL   104.26 (-2.41%)
MSFT   196.89 (-1.75%)
FB   247.50 (-1.99%)
GOOGL   1,431.77 (-1.33%)
AMZN   2,907.50 (-1.60%)
NVDA   477.10 (-2.15%)
TSLA   448.85 (+1.52%)
BABA   268.19 (-1.55%)
GE   6.68 (-2.91%)
MU   49.82 (-1.81%)
AMD   73.92 (-1.35%)
T   28.78 (-0.52%)
F   7.08 (-2.07%)
ACB   6.44 (-1.38%)
GILD   64.46 (-0.91%)
NFLX   464.09 (-1.25%)
DIS   125.74 (-2.25%)
BAC   24.43 (-3.09%)
BA   157.85 (-2.04%)
S&P 500   3,255.58 (-1.92%)
DOW   27,059.34 (-2.16%)
QQQ   262.46 (-1.65%)
AAPL   104.26 (-2.41%)
MSFT   196.89 (-1.75%)
FB   247.50 (-1.99%)
GOOGL   1,431.77 (-1.33%)
AMZN   2,907.50 (-1.60%)
NVDA   477.10 (-2.15%)
TSLA   448.85 (+1.52%)
BABA   268.19 (-1.55%)
GE   6.68 (-2.91%)
MU   49.82 (-1.81%)
AMD   73.92 (-1.35%)
T   28.78 (-0.52%)
F   7.08 (-2.07%)
ACB   6.44 (-1.38%)
GILD   64.46 (-0.91%)
NFLX   464.09 (-1.25%)
DIS   125.74 (-2.25%)
BAC   24.43 (-3.09%)
BA   157.85 (-2.04%)
S&P 500   3,255.58 (-1.92%)
DOW   27,059.34 (-2.16%)
QQQ   262.46 (-1.65%)
AAPL   104.26 (-2.41%)
MSFT   196.89 (-1.75%)
FB   247.50 (-1.99%)
GOOGL   1,431.77 (-1.33%)
AMZN   2,907.50 (-1.60%)
NVDA   477.10 (-2.15%)
TSLA   448.85 (+1.52%)
BABA   268.19 (-1.55%)
GE   6.68 (-2.91%)
MU   49.82 (-1.81%)
AMD   73.92 (-1.35%)
T   28.78 (-0.52%)
F   7.08 (-2.07%)
ACB   6.44 (-1.38%)
GILD   64.46 (-0.91%)
NFLX   464.09 (-1.25%)
DIS   125.74 (-2.25%)
BAC   24.43 (-3.09%)
BA   157.85 (-2.04%)
S&P 500   3,255.58 (-1.92%)
DOW   27,059.34 (-2.16%)
QQQ   262.46 (-1.65%)
AAPL   104.26 (-2.41%)
MSFT   196.89 (-1.75%)
FB   247.50 (-1.99%)
GOOGL   1,431.77 (-1.33%)
AMZN   2,907.50 (-1.60%)
NVDA   477.10 (-2.15%)
TSLA   448.85 (+1.52%)
BABA   268.19 (-1.55%)
GE   6.68 (-2.91%)
MU   49.82 (-1.81%)
AMD   73.92 (-1.35%)
T   28.78 (-0.52%)
F   7.08 (-2.07%)
ACB   6.44 (-1.38%)
GILD   64.46 (-0.91%)
NFLX   464.09 (-1.25%)
DIS   125.74 (-2.25%)
BAC   24.43 (-3.09%)
BA   157.85 (-2.04%)
Log in
NASDAQ:ACRS

Aclaris Therapeutics Stock Forecast, Price & News

$2.53
-0.01 (-0.39 %)
(As of 09/18/2020 12:00 AM ET)
Add
Compare
Today's Range
$2.39
Now: $2.53
$2.77
50-Day Range
$1.95
MA: $2.28
$2.71
52-Week Range
$0.70
Now: $2.53
$3.34
Volume41,658 shs
Average Volume610,466 shs
Market Capitalization$108.09 million
P/E RatioN/A
Dividend YieldN/A
Beta1.35
Aclaris Therapeutics, Inc., a biopharmaceutical company, focuses on identifying, developing, and commercializing various therapies for dermatological and immuno-inflammatory diseases in the United States. It operates in two segments, Dermatology Therapeutics and Contract Research. The company offers ESKATA, a formulation of high-concentration hydrogen peroxide topical solution for raised seborrheic keratosis, a common non-malignant skin tumor; and RHOFADE, an oxymetazoline hydrochloride cream. It is also developing A-101, a high-concentration formulation of hydrogen peroxide that is in Phase III clinical trial for common warts; and ATI-501 and ATI-502 Janus kinase (JAK) inhibitors, which are in Phase II clinical trials for alopecia areata (AA) and other dermatological indications. In addition, the company's products under development include ATI-450 MK-2 pathway oral inhibitor for the treatment of rheumatoid arthritis, psoriasis, hidradenitis suppurativa, cryopyrin-associated periodic syndrome, and pyoderma gangrenosum; ATI-1777 JAK1/JAK3 soft topical inhibitor for atopic dermatitis, vitiligo, and alopecia areata; ITK/JAK3 soft topical and oral inhibitors to treat psoriasis and inflammatory diseases; MK-2 pathway oral inhibitor for oncology; and ITK-JAK3 oral gut-restricted inhibitor for ulcerative colitis/Crohn's disease. Further, it provides contract research laboratory services. Aclaris Therapeutics, Inc. has a license and collaboration agreement with Rigel Pharmaceuticals, Inc. for the development and commercialization of JAK inhibitors. The company was founded in 2012 and is headquartered in Wayne, Pennsylvania.
Read More
Aclaris Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.85 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ACRS
CUSIPN/A
Phone484-324-7933

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$4.23 million
Book Value$1.69 per share

Profitability

Net Income$-161,350,000.00
Net Margins-1,827.81%

Miscellaneous

Employees169
Market Cap$108.09 million
Next Earnings Date11/5/2020 (Estimated)
OptionableOptionable
$2.53
-0.01 (-0.39 %)
(As of 09/18/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ACRS News and Ratings via Email

Sign-up to receive the latest news and ratings for ACRS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Aclaris Therapeutics (NASDAQ:ACRS) Frequently Asked Questions

How has Aclaris Therapeutics' stock been impacted by COVID-19?

Aclaris Therapeutics' stock was trading at $1.06 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, ACRS shares have increased by 138.7% and is now trading at $2.53.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Aclaris Therapeutics?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aclaris Therapeutics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Aclaris Therapeutics
.

When is Aclaris Therapeutics' next earnings date?

Aclaris Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020.
View our earnings forecast for Aclaris Therapeutics
.

How were Aclaris Therapeutics' earnings last quarter?

Aclaris Therapeutics Inc (NASDAQ:ACRS) announced its earnings results on Friday, August, 7th. The biotechnology company reported ($0.28) EPS for the quarter, topping the consensus estimate of ($0.36) by $0.08. The biotechnology company had revenue of $2.05 million for the quarter, compared to the consensus estimate of $1.25 million. Aclaris Therapeutics had a negative return on equity of 105.38% and a negative net margin of 1,827.81%.
View Aclaris Therapeutics' earnings history
.

Are investors shorting Aclaris Therapeutics?

Aclaris Therapeutics saw a drop in short interest in August. As of August 31st, there was short interest totaling 671,700 shares, a drop of 19.7% from the August 15th total of 836,700 shares. Based on an average trading volume of 800,300 shares, the days-to-cover ratio is presently 0.8 days. Approximately 2.1% of the shares of the stock are short sold.
View Aclaris Therapeutics' Short Interest
.

Who are some of Aclaris Therapeutics' key competitors?

What other stocks do shareholders of Aclaris Therapeutics own?

Who are Aclaris Therapeutics' key executives?

Aclaris Therapeutics' management team includes the following people:
  • Dr. Neal S. Walker D.O., Co-Founder, CEO, Pres & Director (Age 49)
  • Mr. Christopher V. Powala, Co-Founder and Chief Regulatory & Devel. Officer (Age 60)
  • Dr. Stuart D. Shanler, Co-Founder & Chief Scientific Officer (Age 58)
  • Mr. Frank Ruffo, Co-Founder & CFO (Age 53)
  • Ms. Kamil Ali-Jackson J.D., Co-Founder, Chief Legal Officer, Chief Compliance Officer & Sec. (Age 60)

What is Aclaris Therapeutics' stock symbol?

Aclaris Therapeutics trades on the NASDAQ under the ticker symbol "ACRS."

Who are Aclaris Therapeutics' major shareholders?

Aclaris Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Telemetry Investments L.L.C. (1.11%), Bridgeway Capital Management Inc. (0.64%), Jane Street Group LLC (0.47%), Schonfeld Strategic Advisors LLC (0.46%), Bank of New York Mellon Corp (0.26%) and Verition Fund Management LLC (0.15%). Company insiders that own Aclaris Therapeutics stock include Anand Mehra, James E Flynn and Stephen A Tullman.
View institutional ownership trends for Aclaris Therapeutics
.

Which institutional investors are selling Aclaris Therapeutics stock?

ACRS stock was sold by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, WINTON GROUP Ltd, Charles Schwab Investment Management Inc., Telemetry Investments L.L.C., and Two Sigma Advisers LP.
View insider buying and selling activity for Aclaris Therapeutics
.

Which institutional investors are buying Aclaris Therapeutics stock?

ACRS stock was bought by a variety of institutional investors in the last quarter, including Bridgeway Capital Management Inc., Jane Street Group LLC, Schonfeld Strategic Advisors LLC, Verition Fund Management LLC, Virtu Financial LLC, and Goldman Sachs Group Inc.. Company insiders that have bought Aclaris Therapeutics stock in the last two years include Anand Mehra, and Stephen A Tullman.
View insider buying and selling activity for Aclaris Therapeutics
.

How do I buy shares of Aclaris Therapeutics?

Shares of ACRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Aclaris Therapeutics' stock price today?

One share of ACRS stock can currently be purchased for approximately $2.53.

How big of a company is Aclaris Therapeutics?

Aclaris Therapeutics has a market capitalization of $108.09 million and generates $4.23 million in revenue each year. The biotechnology company earns $-161,350,000.00 in net income (profit) each year or ($2.25) on an earnings per share basis. Aclaris Therapeutics employs 169 workers across the globe.

What is Aclaris Therapeutics' official website?

The official website for Aclaris Therapeutics is www.aclaristx.com.

How can I contact Aclaris Therapeutics?

Aclaris Therapeutics' mailing address is 640 LEE ROAD SUITE 200, WAYNE PA, 19087. The biotechnology company can be reached via phone at 484-324-7933 or via email at [email protected]

This page was last updated on 9/21/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.